{
  "basic_info": {
    "symbol": "KNSA",
    "name": "Kiniksa Pharmaceuticals Ltd",
    "sector": "LIFE SCIENCES",
    "industry": "PHARMACEUTICAL PREPARATIONS",
    "country": "USA",
    "currency": "USD"
  },
  "market_data": {
    "market_cap": "2369964000",
    "shares_outstanding": "43472900",
    "52_week_high": "32.15",
    "52_week_low": "17.82",
    "50_day_ma": "28.3",
    "200_day_ma": "23.51"
  },
  "valuation_ratios": {
    "pe_ratio": "639.6",
    "peg_ratio": "None",
    "price_to_book": "4.788",
    "price_to_sales": "4.477",
    "ev_revenue": "3.914",
    "ev_ebitda": "346.65"
  },
  "profitability_metrics": {
    "profit_margin": "0.009",
    "operating_margin_ttm": "0.129",
    "return_on_assets_ttm": "0.0047",
    "return_on_equity_ttm": "0.0103",
    "gross_profit_ttm": "281152000"
  },
  "financial_strength": {
    "revenue_ttm": "529332000",
    "revenue_per_share_ttm": "7.3",
    "quarterly_revenue_growth": "0.443",
    "quarterly_earnings_growth": "5.5",
    "book_value": "6.69",
    "diluted_eps_ttm": "0.05"
  },
  "dividend_info": {
    "dividend_per_share": "None",
    "dividend_yield": "None",
    "dividend_date": "None",
    "ex_dividend_date": "None"
  },
  "technical_indicators": {
    "beta": "0.046",
    "analyst_target_price": "45.17",
    "trailing_pe": "639.6",
    "forward_pe": "-"
  }
}